4 курс / Дерматовенерология / Диссертация_Рауш_Е_Р_Особенности_возбудителей_внутрибольничного

131

59.Doyle, J. J. A rapid DNA isolation procedure for small quantities of fresh leaf tissue / J. J. Doyle, J. L. Doyle // Phytochem. Bull. – 1987. – Vol.19. –

P.11-15.

60.Doyle S. Fungal proteomics: from identifcation to function / S. Doyle // Jour. Federation of European Microbiological Societies. – 2011. – Vol.321.

– P.18-23.

61.Eksi F. In Vitro Susceptibility of Candida Species to Four Antifungal Agents Assessed by the Reference Broth Microdilution Method / F. Eksi, E.

D.Gayyurhan, I. Balci // The Scientific World Journal – 2013. – Vol. 6 . –

P.214-219.

62.Elucidating drug resistance in human fungal pathogens / J.L. Xie , E.J. Polvi, T. Shekhar-Guturja // Future Microbiol. – 2014. – Vol.9. – P.523– 542.

63.ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedure / M. Cuenca-Estrella, P. E. Verweij, M. C. Arendrup et al. //Clinical Microbiology and Infection diseases. – 2012. – Vol.18.suppl. 7. – P.9-18.

64.Epidemiology of invasive fungal infections in the intensive care unit: Results of a multicenter Italian survey (AURORA Project) / M.T. Montagna, G. Caggiano, G. Lovero et al. // Infection. – 2013. – Vol.41. – P. 645–653.

65.Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain / M. PuigAsensio, B. Padilla, J. Garnacho-Montero et al. // Clin Microbiol Infect. – 2014. – Vol.20. – O245-254.

66.Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance) registry, 2004–2008 / M. Pfaller, D. Diekema, H.-U. Meier-Kriesche et al. // Diagnostic Microbiology & Infectious Disease. – 2012. – Vol.74. – P.323–331.

132

67.Evaluation of New Colorimetric Vitek 2 Yeast Identification Card by Use of Different Source Media / G. Valenza, J. Strasen, F. Schäfer et al. // J. Clin. Microbiol. – 2008. – Vol.46. – P.3784-3787.

68.Evolution of Mating within the Candida parapsilosis Species Group / S. Sixiang , L. M. Holland, C. F. McGee et al. // Eukaryot Cell. –2011. – Vol.10. – P. 578–587.

69.Evolution of pathogenicity and sexual reproduction in eight Candida genomes / G. Butler, M. D. Rasmussen, M. F. Lin et al // Nature. – 2009. – Vol. 459. – P.657-662.

70.Espinel-Ingroff A.V. Medical Mycology in the United States. A historical analysis (1894-1996) / A.V. Espinel-Ingroff // Mycopathologia – 2005. – Vol/ 160/ - P. 187-188.

71.Espinel-Ingroff A. EUCAST and CLSI: Working Together Towards a Harmonized Method for Antifungal Susceptibility Testing / A. EspinelIngroff, M.Cuenca-Estrella, E. Cantón // Clinical Microbiology and Infection. – 2013. – Vol.7. – p 59-67

72.Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational study in France (2005–2006) / O. Leroy, J.-P. Gangneux et al. // Crit. Care Med. – 2009. – Vol.37. – P. 1612-1618.

73.Espinel-Ingroff A. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole / A. Espinel-Ingroff, F. Barchiesi, M. Cuenca-Estrella // J. Clin. Microbiol. – 2005. – Vol.43. – P.3884-3889.

74.Espinel-Ingroff A. EUCAST and CLSI: Working Together Towards a Harmonized Method for Antifungal Susceptibility Testing / A. EspinelIngroff, M. Cuenca-Estrella, E. Cantуn // Clinical Microbiology and Infection. – 2013. – Vol.7. – P.59-67

133

75.European Committee for Antifungal Susceptibility Testing (EUCAST). Method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts // EUCAST definitive document EDef 7.1. – 2004. – EUCAST, Geneva.

76.Evaluation of VITEK 2 and RapID yeast plus systems for yeast species identification: experience at a large clinical microbiology laboratory. / M. Sanguinetti, Porta, M. Sali et al. // J. Clin. Microbiol. – 2007. – Vol.45. – P.1343–1346.

77.First report of a clinical isolate of Candida haemulonii in Brazil / J.Nobrega de Almeida, A. Lopes Motta, F. Rossi et al. // Clinics (Sao Paulo). – 2012. Vol.67. – P.1229–1231.

78.Fleck R. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. / R. Fleck, D. Annebärbel, H. Herbert // J. Antimicrob. Chemother. – 2007. – Vol.59. – P. 767–771.

79.FUNGEMYCA Study Group Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey / J. Pemán, E. Cantón, G. Quindós, et al. // Journal of

Antimicrobial Chemotherapy. – 2012. – Vol. 67. – Suppl. 5. – P. 1181– 1187.

80.Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection / D. M. MacCallum, A. Coste, F. Ischer et al. // Antimicrob. Agents Chemother. – 2010. – Vol. 54. – P.1476–1483.

81.Gundes S. G. Comparative performance of Fungichrom I, Candifast and API 20C Aux systems in the identification of clinically significant yeasts / S.

G. Gundes, S. Gulenc, R. Bingol // J. Med. Microbiol. – 2011. – Vol. 50. –

p.1105-1110.

134

82.Guinea J. Global trends in the distribution of Candida species causing candidemia / J. Guinea // Clin. Microbiol. and Infect. – 2014. – Vol.20, Suppl.6. – P.5–10.

83.Hameed S. Novel regulatory mechanisms of pathogenicity and virulence to combat MDR in Candida albicans / S. Hameed, Z. Fatima // Int. J. Microbiol. – 2013. - Vol.2013 – P.1-10.

84.Hidden Killers: Human Fungal Infections / G. D. Brown, D. W. Denning, A. R. Gow et al. // Sci. Transl. Med. – 2012. – Vol. 4. – P.165

85.Improved clinical laboratory identification of human pathogenic yeasts by matrix-assisted laser desorption ionization time-of-flight mass spectrometry / O. Bader, M. Weig, L. Taverne-Ghadwal et al. // Clin Microbiol Infect. – 2011. – Vol.17. – P.1359-65.

86.Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a populationbased active surveillance program / R. A. Hajjeh, A. N. Sofair, L. H. Harrison et al. // J. Clin. Microbiol. – 2004. – Vol.42. – P.1519–1527.

87.Invasive candidiasis in pediatric intensive care in Greece: a nationwide study / L. Vogiatzi, S. Ilia, G. Sideri et al. // Intensive Care Medicine. – 2013. – Vol. 39. – P. 2188 – 2195.

88.Invasive candidemia in Norway a comparison of 2 decades / L. Hesstvedt, P. Gaustad, R. Hannula et al. // Mycoses. – 2013. – Vol.56. – 15.

89.Invasive infections due to Candida norvegensis and Candida inconspicua: report of 12 cases and review of the literature / J. Guitard, A. Agoulvant, V. Letscher-Bru et al. // Medical Mycology. – 2013. – Vol.51. – P.795-799.

90.Iwen P.C. Utilization of the internal transcribed spacer regions as molecular targets to detect and identify human fungal pathogens / P. C. Iwen, S. H. Hinrichs, M. E. Rupp // Med Mycol. – 2002. – Vol. 40. – P.87-109.

91.Jamal W. Y. Comparative evaluation of two matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)

135

systems for the identification of clinically significant yeasts / W.Y. Jamal, S.

Ahmad // Intern. J. Infect. Dis. – 2014. – Vol.26. – P. 14-21.

92.Khardori N. Future of diagnostic microbiology / N. Khardori // Indian J Med Microbiol. – 2014. – Vol. 32. – P. 371-377.

93.Kofteridis D.P. Caspofungin-non-susceptible Candida isolates in cancer patients / D.P. Kofteridis, R. E. Lewis, D. P. Kontoyiannis // Journal of Antimicrobial Chemotherapy. – 2010. – Vol.65. – P. 293-295.

94.Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance / A. J. Barnes // J. hosp.infect. – 2002. – Vol.50. – P.243-260.

95.Kurtzman C. P. Systematics and taxonomy of yeasts / C. P. Kurtzman // Contrib. Microbiol. – 2000. – Vol.51. – P.14.

96.Kwon-Chung K. J. Phylogenetic spectrum of fungi that are pathogenic to humans / K.J. Kwon-Chung // Clinical Infect. Dis. – 1996. – Vol.19. – P.1-7.

97.Lachance M.-A. Kluyveromyces van der Walt (1971)/ M.-A. Lachance, T. Boekhout, J.W. Fell // The yeasts: a taxonomic study / C.P. Kurtzman, J.W.Fell, T. Boekhout (eds.) – Elsevier Science & Technology, Amsterdam, 2011. – Р. 477-479.

98.Laboratory biosafety manual. WHO. 3rd ed – Geneva, 2004. – 170 p.

99.Latin American Invasive Mycosis Network. Epidemiology of candidemia in Latin America: a laboratory-based survey / M. Nucci, F. Queiroz-Telles, T. Alvarado-Matute et al. // PLoS ONE. – 2013. – Vol.8. – e59373.

100.Li T. Y. Characterization of Aspergillus spores by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry / T. Y. Li, B. H. Liu,

Y. C. Chen // Rapid Commun. Mass Spectrom. – 2000. – Vol.14. – P.2393–

2400.

101.Matrix-assisted laser desorption ionization-time of flight mass spectrometry for fast and reliable identification of clinical yeast isolates / G. Marklein, M. Josten, U. Klanke et al. // J. Clin. Microbiol. – 2009. – Vol.47. –P.2912- 2917.

136

102.Matrix-assisted ultraviolet-laser desorption of nonvolatile compounds / M. Karas, D. Bachmann, D. Bahr et al. //Int. J. Mass Spectrom. Ion Proc. – 1987. – Vol. 78. – P. 53-68.

103.MALDI Biotyper 3.1. User manual revision 1. Bruker Daltonics. – Bremen.

– 2012. – 212 p.

104.MALDI-TOF MS: an upcoming tool for rapid detection of antibiotic resistance in microorganisms / M. Kostrzewa, K. Sparbier, T. Maier et al. // Prot. Clin. Appl. – 2013. –Vol.7. – P.767–778.

105.McIlroy, M. A. Failure of fluconazole to suppress fungemia in a patient with fever, neutropenia, and typhilitis / M. A. McIlroy // J. Infect. Dis. – 1991. – Vol.163. – P.420–421.

106.MFS multidrug transporters in pathogenic fungi: do they have real clinical impact? / C. Costa, P. J. Dias, I. Sá-Correia et al. // Front. Physiol. – 2014. – Vol. 5. – P.197.

107.Mnichowska-Polanowska M. In vitro susceptibility testing of candida albicans by using Micronaut-Am method / M. Mnichowska-Polanowska // Mycoses – 2013. - Vol. 56. – P.68.

108.Multicenter Evaluation of the New VITEK 2 Advanced Colorimetric Yeast Identification Card / D. J. Hata, L. Hall, A.W. Fothergill et al. // J Clin Microbiol. – 2007. – Vol. 45. – P.1087–1092.

109.Multicenter Comparison of the Vitek 2 Antifungal Susceptibility Test with the CLSI Broth Microdilution Reference Method for Testing Caspofungin, Micafungin, and Posaconazole against Candida spp. / J. F. Peterson, M. A. Pfaller, D. J. Diekema et al. // J. Clin. Microbiol. – 2011. – Vol.49. – P.1765–1771.

110.Messer S.A. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003) / S. A. Messer, R. N. Jones, T.R. Fritsche // J. Clin. Microbiol. – 2006. – Vol.44. – P.1782-1787.

137

111.Metabolic control of antifungal drug resistance / N. Robbins , C. Collins , J. Morhayim et al. // Fungal Genet. Biol. – 2010. – Vol. 47. – P.81–93.

112.Molecular Identification and Antifungal Susceptibility Testing of Clinical Isolates of the Candida rugosa Species Complex and Proposal of the New Species Candida neorugosa / K. Paredes, A. Deanna, J. Sutton et al. //J. Clin. Microbiol. – 2012. – Vol. 50. – P. 2397-2403.

113.Molecular Identification and Antifungal Susceptibility of Yeast Isolates Causing Fungemia Collected in a Population-Based Study in Spain in 2010 and 2011/ J. Guinea, O. Zaragoza, P. Escribano et al. // Antimicrob Agents Chemother. – 2013. – Vol.58. – P. 1529-1537.

114.Moran G, Coleman D, Sullivan D. An introduction to the medically important Candida Species / R. A. Calderone, C. J. Clancy // Candida and Candidiasis / R. A. Calderone, C. J. Clancy. (eds). – ASM Press, Washington, DC, 2002. – P. 1127.

115.National surveillance of fungemia in Denmark (2004 to 2009) / M. C. Arendrup, B. Bruun, J. J. Christensen et al. // J Clin Microbiol. – 2011. – Vol.49. – P.325–334.

116.No increase in primary nosocomial candidemia in 682 German intensive care units during 2006 to 2011/ E. Meyer, C. Geffers, P. Gastmeier et al. // Euro Surveill. – 2013. – Vol.18. – P.10-12.

117.Odds F. C. One year prospective survey of Candida bloodstream infections in Scotland / F. C. Odds, M. F. Hanson, A. D. Davidson // J. Med. Microbiol.

– 2007. – Vol.56. – P. 1066–1075.

118.Page B. T. Rapid identification of Candida species and other clinically important yeast species by flow cytometry / B. T. Page, C. P. Kurtzman // J. Clin. Microbiol. – 2005. – Vol.43. – P.4507-4514.

119.Pappas P. G. Antifungal Clinical Trials and Guidelines: What We Know and Do Not Know / P. G. Pappas // Cold Spring Harbor Perspectives in medicine. – 2014. – Vol.12. – P. 15-21

138

120.Pappas PG. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America / Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr // Clinical Infection Diseases. – 2009. – Vol.48. – P.503-535.

121.PCR protocol for specific identification of Candida nivariensis, a recently described pathogenic yeast / J. Alcoba-Flórez , M. del Pilar, F.J. A.

González-Paredes et al. // J. Clin. Microbiol. – 2005. – Vol.43. – P. 6194– 6196.

122.Perlin D.S. Antifungal drug resistance: do molecular methods provide a way forward? / D. S. Perlin // Curr. Opin. Infect. Dis. – 2009. – Vol.22. – P.568– 573.

123.Perlroth J. Nosocomial fungal infections: epidemiology, diagnosis, and treatment / J. Perlrot, B. Choi, B. Spellberg // Medical Mycology. – 2007. – Vol.45. – P. 321-346.

124.Pestova L. Candidemia at intensive care units (ICU) in Saint-Petersburg, Russia / Pestova L., Klimko N., Bogomolova T. et al. // Clinical microbiology and infection. – 2004. – Vol. 10. – P.639-640.

125.Pfaller M.A. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment / M. A. Pfaller // Am. J. Med. – 2012. – Vol.125. – S3–S13.

126.Pfaller M. A. Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 Systemically active antifungal agents when tested against Candida spp. / M. A. Pfaller, M. Castanheira // Diagnostic Microbiology and Infectious Disease. – 2014. – Vol.79. –P.198– 204.

127.Pfaller M. A. Triazole and Echinocandin MIC Distributions with Epidemiological Cutoff Values for Differentiation of Wild-Type Strains from Non-Wild-Type Strains of Six Uncommon Species of Candida / M. A. Pfaller, M. Castanheira, D. J. Diekema // J. Clin. Microbiol. – 2011. – Vol.49. – P. 3800–3804.

139

128.Pfaller M. A. Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem / M. A. Pfaller,D. J. Diekema // Clin. Microbiol. Rev. – 2007. – Vol.20. – P.133–163.

129.Pfaller M. A. Candida guilliermondii, an Opportunistic Fungal Pathogen with Decreased Susceptibility to Fluconazole: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program / M. A. Pfaller, D. J. Diekema, M. Mendez // J.Clin.Microbiol. – 2006. – Vol. 44. – P.3551–3556.

130.Population structure and properties of Candida albicans, as determined by multilocus sequence typing / A. Tavanti, A.D. Davidson, M.J. Fordyce et al. // J. Clin. Microbiol. – 2005. – Vol. 43. – P.5601–5613.

131.Prevalence of Candida bracarensis and Candida nivariensis in a Spanish collection of yeasts: comparison of results from a reference centre and from a population-based surveillance study of candidemia / M. Cuenca-Estrella, A. Gomez-Lopez, G. Isla et al. // Med Mycol. – 2011. –Vol. 49. – P.525529.

132.Protein and polymer analyses up to m⁄z 100000 by laser ionization time-of- flight mass-spectrometry / K. Tanaka, H. Waki, Y. Ido et al. // Rapid Commun. Mass Spectrom. – 1988. – Vol. 2. – P. 151-153.

133.Qiao-Ting C. Comparison of the Accuracy of Two Conventional Phenotypic Methods and Two MALDI-TOF MS Systems with That of DNA Sequencing Analysis for Correctly Identifying Clinically Encountered Yeasts / C. Qiao-Ting, L.Tai-Fen, T. Shih-Hua // J Clin Microbiol. – 2014.

– Vol.60. – P. 3225–3235.

134.Quantitation of Candida CFU in Initial Positive Blood Cultures /Christopher D. Pfeiffer, Gregory P. Samsa et al. // Journal of Clinical Microbiology. – 2011. – Vol.49, p.2879–2883.

135.Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-Year Analysis of Susceptibilities of Candida and Other Yeast Species to Fluconazole and Voriconazole by Standardized Disk Diffusion Testing / M.

140

A. Pfaller, D. J. Diekema, M. G. Rinaldi et al. //J. Clin. Microbiol. – 2005. – Vol.43. – P.5848–5859.

136. Raju S.B. Isolation and Identification of Candida from the Oral Cavity / S. B. Raju, Rajappa S. // International Scholarly Research Notices. – 2011. – Vol. 201. – P. 1-8.

137.Rapid Emergence of Echinocandin Resistance during Candida kefyr

Fungemia Treatment with Caspofungin / A. Fekkar, I. Meyer, J. Y. Brossas

// Antimicrob. Agents Chemother. – 2013. – Vol.57. – P.2380–2382.

138.Rapid antifungal susceptibility testing by matrix-assisted laser desorption ionization-time of flight mass spectrometry analysis / A. Vella, E. De Carolis, L. Vaccaro et al. / J. Clin. Microbiol. – 2013. – Vol.51. – P. 2964– 2969.

139.Rapid identification and susceptibility testing of Candida spp. from positive blood cultures by combination of direct MALDI-TOF mass spectrometry and direct inoculation of Vitek 2 / E. A. Idelevich, C. M. Grunewald, J.

Wüllenweber et al. // (2014) PLoS ONE 9: e114834].

140.Recommendations for the diagnosis of candidemia in Latin America / A. Lopes Colombo, J. A. Cortes J. Zurita et al. // Revista Iberoamericana de

Micología. – 2013. – Vol. 30. – P.150–157.

141.Reiss E., Shadomy H.J., Lyon G.M. Fundamental medical mycology. – 2011. – 624p.

142.Resistance of Candida spp. to antifungal drugs in the ICU: where are we now? / D. Maubon, C. Garnaud, T. Calandra et al. // Intensive Care Med. – 2014. – Vol.40. – P.1241–1255.

143.Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of Candida Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion / M.A. Pfaller, D.J. Diekema, D. L. Gibbs et al. // J Clin Microbiol. – 2010. – Vol.48. – P. 1366–1377.